Three months after the entry of health care focused investment firm ArchiMed, SUANFARMA (Fairlawn, NJ) has reached an agreement to acquire a majority of Monteloeder, a world leader in the research and development of scientifically proven and patent-protected botanical extracts supported by clinical studies.
With more than 25 years in the market, Monteloeder has experienced strong international growth with a relevant presence in the U.S. and several Asian countries, according to the company. SUANFARMA aims to expand Monteloeder’s product offering into the group’s core markets and capitalize on Monteloeder’s market-leading R&D Department to strengthen the development of scientifically proven branded ingredients.
With this acquisition, SUANFARMA said it has taken a major step forward, significantly strengthening its development and industrial capabilities in the nutritional sector, which enriches the groups’ capabilities with its own manufacturing and development capabilities for nutraceutical ingredients. This agreement will further develop the group’s presence in areas such as weight management, cardiovascular health, nutricosmetics, and relaxation and sleep enhancement.
Both companies said they are committed to innovation, development and sustainability, working on applied research that anticipates market needs, developing solutions in line with market demands based on clinical studies.
For more information, visit www.suanfarma.com/en/.